1. |
Goto S, Shirotani N, Hatakeya M, et al. Clinical benefit of
non-toxic therapy in patients with advanced cancer (opinion). Anticancer
Research 2002; 22(4): :2461-2464
|
| 2. |
馬場雅行、山口 豊、藤沢武彦ら 肺癌術後局所再発および転移性肺腫瘍し対する局所療法 癌と化学療法 1988;
15(4): 1342-1350
|
| 3. |
Komatsu T, Yamauchi K, Furukawa T, et
al. Transcatheter arterial injection of autologous lymphokine-activated
killer (LAK) cells into patients with liver cancers. J Clin
Immunol 1990; 10(3): 167-174
|
| 4. |
関根暉彬 固層化CD3抗体により活性化したT Cell(CD3-LAK)を用いた養子免疫療法 Biotherapy 1990; 4(10):
1606-1613
|
| 5. |
薄井昭博 腎細胞癌患者の養子免疫療法に関する研究 第２編：進行性腎細胞癌に対する血漿交換併用LAK療法 日本泌尿器科学会雑誌 1990; 81(7):
1058-1064
|
| 6. |
山口佳之、高山孝弘、川見弘之ら LAK細胞養子免疫療法の現状と問題点 日本外科学会雑誌 1991; 92(9):
1234-1236
|
| 7. |
中野悦次、岩崎 明、瀬口利信ら 進行腎癌に対するlymphokine-activated
killer cellおよびinterleukin-2による併用療法の有用性ならびにその限界 日本泌尿器科学会雑誌 1991; 82(3):
395-404
|
| 8. |
Aoki Yoichi, Takakuwa K, Kodama S, et
al. Use of Adoptive Transfer of Tumor-infiltrating Lymphocytes
Alone or in Combinetion with Cisplatin-containing Chemotherapy
in Patents with Epithelial Ovarian Cancer Cancer Research 1991; 51
1934-1939
|
| 9. |
野村一雄、藤岡知昭 進行腎癌に対するlymphokine-Activated
Killer (LAK) 細胞とinterleukin-2による併用療法の研究 日本泌尿器科学会雑誌 1993; 84(5):
831-840
|
| 10. |
Ibayashi Y, Yamaki T, Kawahara T, et
al. Effect of local administration of lymphokine-activated
killer cells and interleukin-2 on malignant brain tumor patients. Neurol
Med Chir(Tokyo) 1993; 33(7): 448-457
|
| 11. |
Kimoto Y, Tanaka T, Tanji Y, et al.
Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated
killer cells and interleukin-2 in the adoptive immunotherapy
of patients with malignancies. Biotherapy 1994; 8(1): 41-50
|
| 12. |
竹田省 進行卵巣癌に対する活性化T Cell（CD3-AT)を用いた養子免疫療法の治療効果 J.
Jpn. Soc. Ther. 1995 30(7): 967-971
|
| 13. |
Haruta I, Yamauchi K, Aruga A, et al. Analytical
study of the clinical response to two distinct adoptive immunotherapies
for advanced hepatocellular carcinoma: comparison between LAK
cell and CTL therapy. J Immunother 1996; 19(3): 218-223
|
| 14. |
Tomitra Y, Katagiri A, Saito K, et al.
Adoptive immunotherapy of patients with metastatic renal cell
cancer using lymphokine-activated killer cells, interleukin-2
and cyclophosphamide: long-term results. Int J Urol 1998; 5(1):
16-21
|
| 15. |
有賀淳、高崎 健 CTL療法 血液・腫瘍科 1999; 38(1): 45-52
|
| 16. |
山口佳之、大田耕司、峠哲哉 癌集学的治療における 体外 cell therapyの意義 癌治療と宿主 2000; 12(2):
172-177
|
| 17. |
谷 眞至、谷村 弘、山上裕機 癌特異的免疫療法−CTL療法の現状と将来 癌治療と宿主 2000 12(4):
330-335
|
| 18. |
Ebina T, Ogama N, Shimanuki H, et al.
Life-prolonging effect of immunocell BAK (BRM-activated killer)
therapy for advanced solid cancer patients: prognostic significance
of serum immunosuppressive acidic protein levels Cancer Immunol
Immunother 2003; 52: 555-560
|
| 19. |
Rosenberg SA A new approach
to the therapy of cancer based on the systemic administration
of autologous lymphokine-activated killer cells and recombinant
interleukin-2. Surgery 1986; 100(2): 262-272
|
| 20. |
Rosenberg SA, Lotze MT, Muul LM, et al. A
progress report on the treatment of 157 patients with advanced
cancer using lymphokine-activated killer cells and interleukin-2
or high-dose interleukin-2 alone. N Engl J Med 1987; 316(15):
889-897
|
| 21. |
Steis RG, Urba WJ, Vandermolen LA, et al.
Intraperitoneal lymphokine-activated killer-cell and interleukin-2
therapy for malignancies limited to the peritoneal cavity. J
Clin Oncol 1990; 8(10): 1618-1629
|
| 22. |
Thompson JA, Shulman KL, Benyunes
MC, et al. Prolonged continuous intravenous infusion interleukin-2
and lymphokine-activated killer-cell therapy for metastatic
renal cell carcinoma. J Clin Oncol 1992; 10(6): 960-968
|
| 23. |
Rosenberg SA, LotzeMT, Yang JC,
et al. Prospective randomized trial of high-dose interleukin-2
alone or in conjunction with lymphokine-activated killer cells
for the treatment of patients with advanced cancer. J Natl Cancer
Inst 1993; 85(8): 622-632
|
| 24. |
Aruga A, Yamauchi K, Takasaki K, et al. Induction
of autologous tumor-specific cytotoxic T cells in patients with
liver cancer. Characterizations and clinical Utilization Int.
J.Cancer 1991; 49: 19-24
|
| 25. |
Takayama T, Makuuchi M, Sekine
T, et al. Distribution and therapeutic effect of intraarterially
transferred tumor-infiltrating lymphocytes in hepatic malignancies
Cancer 1991; 68: 2391-2396
|
| 26. |
Toh U, Yamana H, Sueyoshi S, et al. Locoregional
cellular immunotherapy for patients with advanced esophageal
cancer Clin. Cancer Res 2000; 6: 4663-4673
|
| 27. |
Gomez GG, Hutchinson RB, Kruse
CA Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer
Cancer Treat Rev 2001; 27: 375-402
|
| 28. |
Hujita K, Ikarashi H, Takakuwa K, et al. Prolonged
disease-free period in patients with advanced epitherial ovarian
cancer after adoptive transfer of tumor-infiltrating lymphocytes
Clinical Cancer Research 1993; 1: 501-507
|
| 29. |
Kimura H, Yamaguchi Y A phase III randomized
study of interleukin-2 lymphokine-activated killer cell immunotherapy
combined with chemotherapy or radiotherapy after curative or
noncurative resection of primary lung carcinoma Cancer 1997;
80: 42-49
|
| 30. |
Takayama T, Sekine T, Makuuchi M, et al. Adoptive
immunotherapy to lower postsurgical recurrence rates of hepatocellular
carcinoma: a randomized trial Lancet 2000; 356: 802-807
|
